USNA · XBRL financial data

Usana Health Sciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (USNA's year ends in early January)

In millions of dollars	FY 2020Jan 2, 2021	FY 2021Jan 1, 2022	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2023Dec 28, 2024	FY 2025Jan 3, 2026
Revenue from contracts with customers	1,135	1,186	999	921	855	925
Cost of goods and services sold	209	218	194	177	161	201
Gross profit	926	969	805	744	693	724
Research and development	11	11	12	11	12	11
Selling, general and administrative	261	279	262	257	263	337
Total operating expenses	749	798	697	651	627	687
Operating income (loss)	176	170	108	93	66	37
Interest income	3	3	4	10	11	2
Interest expense	1	0	0	0	0	1
Other income (expense)	(1)	(2)	(3)	0	(1)	3
Income tax expense (benefit)	53	54	39	39	34	30
Net income (loss)	125	117	69	64	42	11
Earnings per share, basic USD per share	5.89	5.78	3.60	3.31	2.20	0.58
Earnings per share, diluted USD per share	5.86	5.73	3.59	3.30	2.19	0.58
Weighted average shares, basic millions of shares	21	20	19	19	19	19
Weighted average shares, diluted millions of shares	21	20	19	19	19	19

Fiscal years (USNA's year ends in early January)

In millions of dollars	FY 2020Jan 2, 2021	FY 2021Jan 1, 2022	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2023Dec 28, 2024	FY 2025Jan 3, 2026
Cash and cash equivalents	312	240	288	330	182	158
Inventory	90	98	67	61	70	103
Prepaid and other current assets	23	27	29	26	28	27
Total current assets	425	365	384	418	279	288
Property and equipment, net	100	102	98	100	95	94
Right-of-use asset	—	24	20	18	21	23
Goodwill	17	18	17	17	144	138
Total assets	641	578	597	633	748	743
Accounts payable	18	14	11	10	12	17
Accrued liabilities	—	—	—	10	14	10
Total current liabilities	168	161	144	119	140	129
Lease liability, non-current	—	10	8	5	10	12
Total liabilities	—	—	—	136	162	157
Retained earnings	383	345	392	445	479	466
Total stockholders' equity	442	395	434	497	532	533
Total liabilities and equity	641	578	597	633	748	743
Common shares outstanding (cover page) millions of shares	21	19	19	19	19	18

Fiscal years (USNA's year ends in early January)

In millions of dollars	FY 2020Jan 2, 2021	FY 2021Jan 1, 2022	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2023Dec 28, 2024	FY 2025Jan 3, 2026
Net income (loss)	125	117	69	64	42	11
Stock-based compensation	14	14	13	15	15	14
Depreciation and amortization	14	13	13	13	15	33
Net cash from operating activities	160	121	104	71	61	22
Purchases of property and equipment	15	13	10	14	10	14
Net cash from investing activities	(34)	(14)	(12)	(12)	(213)	(10)
Share repurchases	57	178	25	12	9	28
Net cash from financing activities	(59)	(181)	(30)	(14)	10	(41)
Net change in cash	78	(72)	48	42	(149)	(23)

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Usana Health Sciences	169	223	23*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Altimmune	63	not reported	(24)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288	1	(25)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rigel Pharmaceuticals	61	79	31*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Amarin	157	40	9.2*	not reported	—	Q3 FY26 10-QSep 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Nektar Therapeutics	39	10	(76)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.